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Abstract Natural killer (NK) cells have originally been
identified by their spontaneous cytolytic potential against
tumor cells, which, however, might result from pre-acti-
vation due to prior pathogen exposure. Resting NK cells,
on the contrary, require activation by bystander antigen-
presenting cells to reach their full functional competence.
In this review, we will summarize studies on how dendritic
cells (DCs), the most potent type of antigen-presenting cell,
communicate with human NK cells to activate them in
secondary lymphoid organs and to integrate signals from
activated NK cells at sites of inflammation for their own
maturation. Furthermore, we will review aspects of the
immunological synapse, which mediates this cross-talk.
These studies provide the mechanistic understanding of
how mature DCs can activate NK cells and survive to go on
for the activation of adaptive immunity. This feature of
DCs, to activate different waves of immune responses,
could be harnessed for immunotherapies, including
vaccinations.
Keywords Immunological synapse  DC editing 
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Sites of inflammation
Dendritic and natural killer cell subsets
Classically, dendritic cells (DCs) have been proposed as
professional sentinels that patrol the body, searching for
stress signals [1]. Indeed, DCs are found in peripheral
blood and in nearly every tissue, including the entire set of
lymphoid organs (thymus, lymph nodes, bone marrow,
tonsils and spleen), and non-lymphoid tissues (liver, kid-
ney, skin and gut). Therefore, it is not surprising that these
antigen-presenting cells (APCs) can get in contact with a
vast variety of pathogens and their products, as well as
stress signals released from dying cells. After sensing
disturbances in tissue homeostasis, DCs migrate to sec-
ondary lymphoid tissues to report the nature of the insult
via displaying components of their original environment on
major histocompatibility complex (MHC) molecules, and
reflecting the conditions under which they have taken up
these components, via their particular maturation pattern.
In secondary lymphoid tissues, mature DCs are known to
be superior to other APCs in their capacity to stimulate and
propagate effective immune responses, due to antigen
presentation, the expression of co-stimulatory molecules
and secretion of cytokines and chemokines [2–5]. Never-
theless, it is important to note that this classical view on
DCs is continually getting updated with additional DC
subsets, some of which are resident in secondary lymphoid
tissues and others that develop from monocytes during
inflammation [6–8].
DC biology and its role in the immune system were
originally dissected in mice and, until now, there has been
much more knowledge of the murine DC system than of the
human system. Moreover, the majority of knowledge on
human DC subsets and their development derives from in
vitro studies with peripheral blood DC precursors and
immature DCs. However, and in agreement with the rarity
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and large variety of DC subsets found in mice, several DC
categories can also be identified in human. According to
Shortman and Naik [7], DCs can be categorized into pre-
DCs, conventional DCs and inflammatory DCs. Pre-DCs
include plasmacytoid DCs and monocytes and are charac-
terized by lack of dendrites and DC function in the steady-
state [9]. Conventional DCs (which display dendrites and
DC functions) can be further divided into migratory DCs
and lymphoid tissue-resident DCs. Migratory DCs include
several subsets of blood DCs like CD1c? (BDCA1?) DCs,
CD141? DCs and CD16? DCs [8, 10–13], in addition to
Langerhans cells and dermal DCs [14, 15]. Lymphoid tis-
sue-resident DCs are represented by, for instance, thymic
and splenic DCs. The last category of DCs consists of
inflammatory DCs that are not present in the steady-state,
but can differentiate from precursors upon infection or
stress signals. Inflammatory DCs include Tip DCs (named
after their ability to produce TNF and iNOS) [16]. However,
very little is so far known about the different capacities of
these DC subsets to interact with natural killer (NK) cells,
an aspect of DC biology that requires further investigation.
Maturation of DCs can be achieved by sensing danger
signals (for example, pathogens or their products, necrotic
cells and pro-inflammatory cytokines) through recognition
receptors, which are present on DCs [17–21]. Toll-like
receptors (TLRs) are among the best studied receptors
involved in these processes. Indeed, the expression of a
unique set of TLRs renders each type of DC susceptible to
particular subsets of pathogens and stress signals, and the
outcome of stimulation with TLR ligands can then result in
increased antigen uptake and presentation [22], expression
of co-stimulatory molecules [23], secretion of cytokines
[24, 25], upregulation of chemokine receptors [26] and,
therefore, stimulation of distinct T cell responses (Th1,
Th2, Th17 or Treg) [1, 27, 28]. Thus, DC maturation
mirrors the inflammation conditions in peripheral tissues
and allows the initiation of proper immune responses in
secondary lymphoid tissues.
Although there are some controversies with respect to
TLR expression by different DC subsets, several studies
point to the expression of TLR1, TLR2, TLR3, TLR5,
TLR6 and TLR8 by conventional DCs, isolated from
human blood. Therefore, these DCs can sense bacteria,
virus and fungi, and they produce primarily IL-12, TNF
and IL-6 in response. In contrast, plasmacytoid DCs
express TLR7 and TLR9, which allows them to primarily
sense viruses, and they produce type I IFNs upon activa-
tion. Finally, inflammatory DCs, which have a similar
repertoire of TLRs as conventional DCs, can also respond
to lipopolysaccharide (LPS), due to their expression of
TLR4 [24, 25, 29–33]. Thus, different DC subsets fulfill
distinct and complementary functions in the innate
restriction of infections and initiation of immune responses.
NK cells are among the effector cells that are activated
by mature DCs. NK cells got the attention of the scientific
community due to their ability to spontaneously kill tumor
cells [34, 35]. In addition to their rapid responsiveness, the
lack of somatic antigen receptor rearrangement placed
them in the innate arm of the immune system. Human NK
cells develop from common lymphoid progenitors [36]
and, as in the case of DCs, they can be subcategorized into
several subtypes and can have different activation states.
NK cells were first phenotypically characterized by the
surface presence of CD56 and lack of CD3. Furthermore,
Lanier and colleagues [37] could characterize two main,
functionally distinct subsets of NK cells by the density of
CD56 expression. Therefore, human peripheral blood NK
cells were described as consisting of a predominant
(C95%) CD56dimCD16? subset, further characterized by
high levels of perforin expression and high cytolytic
activity, and a minor (B5%) CD56brightCD16- subset, with
a superior capacity to produce pro-inflammatory cytokines
like IFN-c and TNF [38–40]. Furthermore, in the steady-
state, NK cells can also be found in various lymphoid and
non-lymphoid tissues that contain different NK cell sub-
sets. The reactivity of activated NK cells is guided by sets
of germline-encoded activating and inhibitory receptors
[41, 42]. The main activating NK cell receptors are
NKG2D and the natural cytotoxicity receptors (NCRs)
NKp30, NKp44 and NKp46. NK cells harboring NKG2D
recognize several molecules (e.g., MICA, MICB and
ULBP) that can be upregulated in cells upon infection,
stress or aberrant transformation (reviewed in [43]). In
contrast, the molecules recognized by the activating NCRs
are still being characterized. However, studies point to a
role of NKp30-mediated recognition of BAT3 in cells with
DNA or endoplasmatic reticulum damage [44]. Further-
more, NKp46 and NKp44 seem to interact with
hemagglutinin in viral-infected cells [45, 46], and NKp46
also participates in surveillance of cell division [47]. The
inhibitory receptors (e.g., CD94/NKG2A and killer cell
immunoglobulin-like receptors, KIRs) engage non-classi-
cal and classical MHC class I molecules, respectively. NK
cells integrate these concurrent signaling pathways and, if
activation is stronger than inhibition, they may secrete
cytokines, proliferate and kill the encountered cell. While
the activating NK cell receptors are homogeneously
expressed on all mature NK cell subsets, the inhibitory
receptors are differentially expressed on NK cell subsets
[48, 49]. Therefore, different NK cell populations express a
certain set of inhibitory receptors that can recognize dif-
ferent MHC class I alleles on target cells. Furthermore,
there is an overlapping of these inhibitory receptors among
the different NK cell subsets. This variegated and over-
lapping expression of NK cell receptors in different NK
cell populations might derive from a stochastic regulation
3506 R. Barreira da Silva, C. Mu¨nz
123
of gene expression during NK cell development and might
allow the surveillance of viral-infected or tumor cells that
have downregulated only a limited set of MHC class I
molecules [50].
In conclusion, the complexities of human DC and NK
cell populations mean that different NK cell subsets can
interact with different DC populations and, depending on
the place where the interaction occurs and on the matura-
tion/activation status of the interacting cells, the outcome
of this interaction may functionally differ.
Places of NK cell activation by DCs
Although DCs and NK cells can theoretically interact in
numerous places, due to their wide distribution in the body,
two main locations have been the focus of most studies due
to their crucial physiologic relevance during immune
responses, namely secondary lymphoid organs (SLOs) and
sites of inflammation. SLOs have a complex organization
that allows efficient cell–cell interactions. Indeed, different
hematopoietic and non-hematopoietic cells, as well as res-
ident and migrating/homing cells, make up these structures.
Resting or non-inflamed human lymph nodes harbor a sig-
nificant number of lymphocytes, including NK cells [51,
52]. With a frequency of half the 10% found in peripheral
blood, but 20-fold more lymphocytes being parked in SLOs
than circulating through the peripheral blood at any given
time point, NK cells may be 10 times more abundant in
lymph nodes than in the periphery [53]. Also, in contrast to
peripheral blood NK cells, lymph node NK cells mostly
(around 90%) belong to the CD56bright subset [2, 52].
Indeed, circulating human CD56bright NK cells have been
shown to abundantly express L-selectin, CCR7 and LFA-1,
making them able to traffic and efficiently enter secondary
lymphoid tissues in the steady-state [38, 51, 54–56]. Fur-
thermore, NK cells have been found to be preferentially
localized in the perifollicular T cell zones of lymph nodes
[2, 57–60]. Curiously, in mice, homing of CD27bright NK
cells to lymph nodes seems to be dependent on CXCR3 and
not CCR7 expression [61–63]. In contrast, mouse NK cells
seem to migrate into splenic white pulp due to CCR7 and
CCL21 signaling [64–66]. Furthermore, some studies in
mice seem to indicate that inflammation leads to increased
NK cell migration into the splenic white pulp [67, 68]. Here,
NK cells home to T cell zones, possibly because of their
ability to migrate along fibroblastic reticular cells. Thus,
NK cells traffic through secondary lymphoid tissues, in the
steady-state, and may be recruited at enhanced frequencies
to these tissues during inflammation.
Although in the steady-state immature DCs can slowly
traffic to SLOs [69], maturation leads to the upregulation of
chemokine receptors (including CCR7) on the surface of
peripheral conventional DCs, rendering them more effi-
cient in entering peripheral lymph vessels and in migrating
to SLOs [3, 26, 70–72]. Furthermore, fibroblastic reticular
cells in proximity to high endothelial venules (HEVs),
found in the T cell area of lymph nodes and spleen, are
major producers of CCL21 and CCL19, which concentrate
recently homed CCR7? mDCs around HEVs [73, 74]. In
this way, DCs are able to efficiently find not only T cells, to
which they can present antigen, but also resting CD56bright
NK cells, enriched at these sites, in addition to NK cells
that travel to the spleen upon infection [51, 56, 73].
Therefore, it has become clear that important locations of
DC/NK cell interactions are SLOs and that these tissues
support interactions between mDCs and naı¨ve or resting
NK cells. The mechanisms underlying these interactions
and their outcomes will be reviewed in the following
sections.
In addition, sites of inflammation are an important
source of production of several cytokines and chemokines
like CCL4, CCL5, CX3CL1 CXCL8 and CXCL10, some
of them produced by subsets of dendritic cells [75]. Cir-
culating NK cells can sense them and migrate to sites of
inflammation. In contrast to lymph nodes, both subsets of
NK cells seem to migrate to sites of inflammation, but there
is some debate about the capacity of their retention. The
type of infectious agent that triggers this inflammation
might contribute to the selective enrichment of distinct NK
cell subpopulations. Along these lines, the CD56bright NK
cell subset was found to be enriched in sites of inflam-
mation promoted by autoimmunity, lung cancer lesions and
renal cell carcinoma [76–79]. Activated NK cells prefer-
entially home to these sites for rapid and efficient killing of
damaged cells. In inflamed tissues, activated NK cells can
encounter immature DCs or DCs that are in the process of
maturation and can edit their activation before they migrate
to secondary lymphoid tissues. Thus, editing of DC mat-
uration by activated NK cells probably occurs primarily at
sites of inflammation.
Mechanisms of NK cell activation by DCs
NK cells are highly cytotoxic cells, ready to kill target
cells, without the need of recognition of a specific antigen,
but rather recognizing self-molecules, which are upregu-
lated in response to many forms of cellular stress. These
characteristics make them potent effectors against trans-
formed and infected cells [34, 80, 81]. As exceptions from
these rules, NK cells are able to initiate immune responses
by direct recognition of cells infected with MCMV that
express on their surface the MCMV-encoded protein m157,
which is recognized by the Ly49H receptor on NK cells
[82, 83], and with influenza virus, due to the ability of the
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NKp46 and NKp44 receptors of NK cells to recognize viral
haemagglutinins on the surface of infected cells [45, 46].
However, in recent years, it has become apparent that this
NK cell recognition requires pre-activation by myeloid
APCs [84–89]. This pre-activation is also called NK cell
priming and happens through cell contact with accessory
cells and their presentation and/or secretion of cytokines.
The most important accessory cells involved in NK cell
priming are monocytes, macrophages and DCs. Depending
on the particular conditions of immune activation, distinct
subsets of these APCs will be activated and participate in
NK cell stimulation. Here, we will focus on the signifi-
cance of DCs as accessory cells in NK cell priming
(Fig. 1).
As described in the first section of this review, several
DC subsets exist and they possess various means to
activate NK cells. Type I IFNs (IFNa and IFNb) primarily
trigger NK cell cytotoxicity [90–92] and control IFN-c
production by these lymphocytes by regulating IL-12
production on classical DCs [93–95]. Plasmacytoid DCs
seem to be a very important source of type I IFNs upon
virus infections, as, for example, by MCMV and VSV [95,
96]. CpG motives of the viral genomes are recognized by
TLR9, expressed in endosomes of plasmacytoid DCs, and
lead to secretion of type I IFNs. Nevertheless, several in
vivo studies have demonstrated that there are other sources
for type I IFN production, independent of plasmacytoid
DCs, and, therefore, these cells seem to represent an
important, but not unique, source of this cytokine [95, 97–
99]. On the other hand, recognition of MCMV by con-
ventional DCs leads to selective secretion of IL-12 [100–
102]. In this way, both subsets of DCs are activated,
Fig. 1 Natural killer cell activation by dendritic cells. Dendritic cells
(DCs) patrol the body constantly in their immature stage. 1 Upon
recognition of a stress signal, that can be pathogen-derived, necrotic
cellular debris or pro-inflammatory cytokines, DCs undergo matura-
tion. Some stress signals are detected by toll-like receptors (TLRs).
During maturation, DCs up-regulate chemokine receptors, which
allow them to efficiently migrate into secondary lymphoid organs
(SLOs). 2 There, mature DCs can encounter autologous resting NK
cells. The cross-talk between these cells differs depending on the
nature of the maturation stimulus received by the DC and the
particular subset of DC. Thus, NK cell activation by mature DCs can
be mediated by soluble molecules to different degree. Cytokines like
IL-12, IL-18 and IL-2 induce IFN-c secretion by NK cells.
Furthermore, IL-15 signaling induces NK cell proliferation and
survival, while type I IFNs increases NK cell cytotoxicity. Although
these cytokines can be secreted, their effect, especially when
produced at limited concentrations by mature DCs, can be improved
through conjugation of DCs and NK cells. Furthermore, the direct cell
contact between these two cell types is also important for signals
derived from receptor/ligand pairs. Along these lines, NK group 2D
(NKG2D), glucocorticoid-induced TNF-receptor-related protein
(GITR) and intracellular adhesion protein 1 (ICAM1) were shown
to activate NK cells, after interaction with their cognate ligands
(NKGD2L, GITRL and lymphocyte function-associated lymphocyte
1 (LFA1), respectively) on mature DCs. 3 Even so this cross-talk
enhanced NK cell cytotoxicity, DCs survive this interaction due to the
high expression of MHC class I molecules after maturation, the
presence of inhibitors of granzyme B-mediated apoptosis in mature
DCs, and actin-mediated stabilization of NK cell inhibitory signaling
by MHC class I molecules at the immunological synapse
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leading to complementary cytokine secretion and increased
cytotoxicity of NK cells upon MCMV infection. Further-
more, conventional DCs-derived secretion of type I IFNs
was shown to play a role during HSV1 infection [103]. In
addition to type I IFN-stimulated NK cell cytotoxicity, IL-
12 and IL-18 are the major promoters of IFN-c secretion by
NK cells, and both cytokines can be produced by DCs.
Plasmacytoid and conventional DCs are important sources
of IL-12 during MCMV infection [101, 102, 104]. Fur-
thermore, conventional DCs activate NK cell responses to
EBV via IL-12 [105]. This cytokine was shown to be
particularly important for activation of CD56bright NK cells
of SLOs upon encountering mature conventional DCs [2].
Furthermore, during influenza virus infection, DCs produce
IL-12 and induce IFN-c production by NK cells [90, 106].
Some responses against parasites and bacteria are also
dependent on IL-12/IL-18 production by DCs, [107, 108],
and probably in rare exceptions, as, for example, in
response to infections with the Gram-negative bacterium
Escherichia coli, Granucci and colleagues [109] found that
DC-derived IL-2 secretion has a more prominent role in
activating NK cells to produce IFN-c. In addition to these
cytokines that promote cytokine secretion by NK cells, IL-
15 plays a crucial role in several aspects of NK cell biol-
ogy. Firstly, it is important for the development of these
innate lymphocytes [110–112]. Furthermore, a role of IL-
15 in NK cell survival and proliferation has been docu-
mented [2, 113, 114]. Moreover, it plays an essential role
during priming of protective immune responses [89, 115,
116]. Finally, a recent study showed that prolonged stim-
ulation of NK cells with IL-15/IL-15Ra complexes leads to
an impairment of NK cell activation [117], indicating a
possible role in the negative-feedback mechanism that
regulates NK cell activation. Of note, overstimulation of
NK cells with activating-receptor ligands (e.g., Rae-1 and
m157 that engage the NK cell-activating receptors NKG2D
and Ly49H, respectively) or immune modulators (e.g., type
I IFNs or Corynebacterium parvum) have been shown to
lead to NK cell hyporesponsiveness [118–120]. DCs,
especially Langerhans cells, express high levels of IL-15
and IL-15Ra, and can trans-present it to NK cells
expressing IL-15Rb and c chains. Therefore, DCs act as
accessory cells promoting NK cell survival and prolifera-
tion [113, 121]. Trans-presentation of IL-15 requires close
contact between DCs and NK cells. However, IL-15 is not
the only cytokine that might require conjugation of DCs
and NK cells for efficient signaling. Directed secretion of
DC-derived IL-12 and IL-18 towards the NK cell can be
required for efficient NK cell activation, when the partic-
ular DC maturation conditions allow only limited
production of these cytokines [122, 123]. Indeed, the
contact-dependent transmission of signals is equally
important as signaling via soluble molecules during NK
cell priming by DCs [85, 86, 124]. For example, Plasmo-
dium falciparum infection in humans confers the ability to
conventional DCs to stimulate NK cells to secrete IFN-c in
a contact-dependent manner [125]. Furthermore, viruses
harboring CpG motives upregulate expression of gluco-
corticoid-induced TNF-receptor-related protein (GITR)
ligand by human plasmacytoid DCs, and the interaction of
this molecule with GITR on NK cells leads to the pro-
duction of IFN-c and enhanced cytotoxicity [126].
Activation of DCs with pro-inflammatory cytokines,
especially type I IFNs, promotes upregulation of NKG2D
ligands leading to IFN-c secretion and enhanced NK cell
cytotoxicity [127]. NK cell activation by DCs stimulated
with LPS involves TREM2 (triggering receptor expressed
by myeloid cells 2), an activating immunoreceptor that
signals via KARAP (killer cell activating receptor-associ-
ated protein)/DAP12 (DNAX-associated protein 12) [128].
Furthermore, adhesion molecules have been shown to be
important in the DC/NK cross-talk [113, 129]. Thus,
although DCs activate NK cells primarily via cytokines,
cell contact is important for directed secretion during this
interaction.
These studies suggest that mature DCs migrate to SLOs,
where they activate NK cells in the T cell zones via
directed secretion during conjugation, and these activated
NK cells can then fight infections in the periphery.
The immunological synapse between DCs and NK cells
While incubation of NK cells with recombinant IL-2, IL-12
or IL-15 is sufficient to initiate cytokine production by NK
cells and increase their cytotoxic activity [105, 121], NK
cell activation by DCs is most efficiently performed
through cell contact [113, 122]. This cell contact is medi-
ated through immunological synapses (IS), and, thus, the
study of these structures became imperative for the correct
understanding of NK cell activation by DCs. Studies of IS
with NK cells first focused on the interaction of NK cells
and target cells that were susceptible to NK cell cytotox-
icity. As the outcome of these interactions is the killing of
the target cell, this IS was called cytotoxic synapse [130,
131]. The human cytotoxic NK cell IS has been extensively
studied by direct visualization of cell conjugates with
human primary NK cells or NK cell-like tumor cell lines.
Altogether, these studies allowed the detailed description
of the kinetics of formation and maturation of the cytotoxic
NK cell IS. NK cell-mediated killing of allogeneic, virus-
infected or tumor cells includes an initiation stage that
leads to adhesion of the NK cell to the target cell (forma-
tion of the IS) and initiation of activating NK cell
signaling. The following effector stage comprises reorga-
nization of the NK cell cytoskeleton that culminates in
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filamentous actin polymerization at the interface between
the cells, and polarization of the microtubule organizing
center (MTOC) of NK cells and of cytotoxic granules
towards the target cell. After lytic granule release, the
termination stage begins, with the detachment of the NK
cell from the apoptotic target cell. The detailed kinetics of
molecule migration and signaling at the cytotoxic NK cell
IS have been recently reviewed [132, 133].
During cytotoxic NK cell responses normal somatic
tissue is spared to avoid immunopathology, and NK cell
cytotoxicity is, therefore, tightly regulated. The expression
of autologous MHC class I molecules on the surface of
healthy cells, together with the absence of expression of
activating ligands, inhibits initiation of cytotoxic NK cell
functions [134, 135]. These inhibitory signaling pathways
are also mediated through conjugates between NK cells
and non-susceptible target cells. The interface of these
conjugates is called the non-cytotoxic IS. The non-cyto-
toxic NK cell IS is characterized by the enrichment of
inhibitory signaling molecules at the interface of the two
cells, that inhibit NK cell–cytoskeleton rearrangements and
promote NK cell detachment from the conjugated cell. In
contrast to these classical classifications of NK cell IS,
mature DCs activate NK cells and prevent themselves from
being killed at the same time during their conjugate for-
mation with NK cells [87]; we named this interaction a
regulatory synapse [113]. While classical cytotoxic and
non-cytotoxic NK cell interactions have been studied in
depth, the interactions of NK cells involving regulatory
synapses are just being characterized. Regulatory NK cell
synapses include interactions between resting NK cells and
fully matured DCs (Fig. 2). In this cross-talk, mature DCs
activate NK cells to secret cytokines, to increase their
cytotoxicity, to survive and to proliferate [105, 113, 121],
while they escape at the same time from NK cell cyto-
toxicity to propagate adaptive immune responses. DC
survival from NK cell cytotoxicity relies on several factors.
Firstly, increased MHC class I expression after DC matu-
ration engages inhibitory NK cell receptors, repressing NK
cell cytotoxic activation. Secondly, mature DCs express
protease inhibitors of the serpin family, like protease
inhibitor 9 (PI9), which inhibit granzyme B-mediated
apoptosis [87, 136, 137]. Furthermore, actin-dependent
stabilization of MHC class I molecules at the IS between
NK cells and mDCs might allow the continuous engage-
ment of inhibitory receptors to prevent NK cell cytotoxicity
(Barreira da Silva and Mu¨nz, submitted). These multiple
mechanisms protect DCs from cytotoxicity, while NK cells
are activated at the same time via the IS with mature DCs.
In addition to these inhibitory interactions at the IS
between DCs and NK cells, polarization of NK cell-acti-
vating cytokines to the conjugate interface can be
observed. Semino and colleagues [123] investigated the
interaction between immature DCs and resting NK cells.
They demonstrated the importance of IL-18 accumulating
at the IS for NK cell activation. In addition, the high
mobility group B1 (HMGB1) protein seemed to mediate
DC maturation and survival during this interaction [123,
138]. In addition, LPS-matured DCs were found to elicit
IFN-c production by resting NK cells in a cell contact-
dependent fashion [122]. During this interaction, IL-12 of
DCs polarized to the interface with NK cells. While these
studies analyzed just a single time point after IS formation
and did not optimize DC maturation for NK cell activation,
we investigated the synapse maturation between NK cells
and polyinosinic polycytidylic acid [poly(I:C)] matured
DCs, which allows for maximal NK cell stimulation [105].
These experiments documented that the synapse between
human mature DCs and autologous resting NK cells forms
rapidly (within 1–5 min of coculture) and matures further
after 20 min of interaction [113, 139] (Barreira da Silva
and Mu¨nz, submitted). Maturation is associated with the
polymerization of DC-derived filamentous actin at the IS
(Barreira da Silva and Mu¨nz, submitted). Cytoskeletal
stabilization of the IS was previously observed in stimu-
latory DC/T cell synapses [140, 141]. DC/NK cell
conjugate formation also seems to depend on CX3CL1
signaling [139], as fewer conjugates are formed in the
presence of blocking antibodies against CX3CL1. Upon
conjugate formation, inhibitory and activating molecules
are recruited in a temporally and spatially well-orchestrated
manner. After 1–5 min, inhibitory KIRs and CD94 mole-
cules on the NK cell and MHC class I molecules on the DC
side, as their ligands, polarize to the DC interface with NK
cells [113]. With similar kinetics, the IL-15 receptor
components accumulate at the synapse. Since the interac-
tion between KIRs and CD94 with MHC class I molecules
leads to inhibitory signaling and IL-15 transpresentation is
important for the activation and survival of NK cells, the
synchronized polarization kinetics of all these molecules
could pose problems for the parallel signaling of these
inhibitory and activating pathways. The simultaneous sig-
naling of these molecules seems to be possible because
they may segregate into different domains at the center of
the synapse [113]. In contrast, structural and adhesion
molecules, like talin, filamentous actin and LFA-1, are
located in the peripheral part of the IS [113]. In addition to
these early events, maturation of the interactions between
DCs and NK cells allows, after 20 min, for IL-12 polari-
zation to the interface, which is essential for the stimulation
of IFN-c secretion by NK cells [122, 139]. Furthermore,
maturation of the IS between mature DCs and resting NK
cells also seems to be important for the maintenance of
inhibitory signaling through KIR engagement by MHC
class I molecules, and for prevention of cytotoxic granule
recruitment to the interface (Barreira da Silva and Mu¨nz,
3510 R. Barreira da Silva, C. Mu¨nz
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submitted). Therefore, mDCs seem to stabilize their syn-
apse with resting NK cells by actin polymerization in order
to allow additional stimulatory molecules, like IL-12, to be
polarized towards NK cells, but use this cytoskeletal sta-
bilization at the same time to maintain inhibitory MHC
class I molecules at the synapse to prevent being killed by
NK cells.
All published studies on human DC/NK cell synapses
have used monocyte-derived DCs, but the hallmarks of this
interaction seem to also hold up for HLA-DR?
CD11c?BDCA1? peripheral blood DCs (Barreira da Silva
and Mu¨nz, submitted). Of further note, both subsets of
peripheral blood NK cells can form conjugates with mature
DCs, but the CD56bright NK cell subpopulation seems to
form synapses with mature DCs more readily [113, 142].
This is consistent with SLOs, as sites of CD56bright NK cell
enrichment, being the primary site of interactions between
mature DCs and resting NK cells.
For obvious reasons, the summarized studies on human
DC interactions with NK cells have been confined to in
vitro experiments. However, it remains unclear if the long
lasting interactions of DCs with NK cells in vitro also
occur in vivo. Initially, using an adoptive transfer strategy,
Baje´noff and colleagues [58] demonstrated that NK cells
can conjugate in vivo for longer time intervals with DCs (at
least 25 min), both in the steady-state and upon infection
with Leishmania major. In contrast, a more recent study
has challenged this notion and suggested multiple short
Fig. 2 The immunological synapse between mature dendritic cells
and resting natural killer cells. Upon encounter, dendritic cells (DCs)
and natural killer (NK) cells rapidly form conjugates, forming an
immunological synapse (IS). The IS between mature DCs and resting
NK cells has both activating and inhibitory features and can,
therefore, be described as a regulatory synapse. The immature IS
between DCs and NK cells (formed after 1–5 min of interaction)
presents enrichment of both activating [IL-15R, talin, lymphocyte
function associated molecule 1 (LFA-1)] and inhibitory [killer cell
immunoglobulin like receptors (KIRs), CD94 and MHC class I]
molecules at the IS (left side). The parallel signaling of these
opposing interactions is possible due to the spatial separation of
activating and inhibitory domains in the IS, which cluster IL-15R,
MHC class I, KIRs and CD94 molecules in the central part of the IS
and are surrounded by talin and LFA-1 molecules. Upon maturation
of the synapse (after 15–20 min of interaction), DCs-derived
filamentous actin polymerized at the interface between the cells
(right side). Furthermore, IL-12 and IL-12R accumulate at the IS,
while IL-15R and MHC class I polarization to the synapse is
maintained. The maintenance of inhibitory signaling via MHC class I
prevents polarization of the cytolytic machinery, like perforin-
containing granules and the microtubule organizing center (MTOC),
to the synapse. The synchronized signaling of activating and
inhibitory molecules allows NK cell activation and inhibition of DC
lysis by NK cells at the same time. Microscopy pictures represent
conjugates between poly(I:C) matured DCs and autologous resting
NK cells after 1 (left) and 20 min (right) of co-culture. Filamentous
actin (green) and nuclear DNA (blue) were stained. Original
magnifications 9100, scale bars 10 lm
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contacts of below 5 min duration for the interactions of NK
cells with DCs in lymph nodes, both in the steady-state and
after poly (I:C) or LPS activation [59]. Therefore, it would
be interesting to discover which pattern of NK cell motility
human NK cells follow in vivo, and novel mouse models
with human immune compartment reconstitution might
allow the addressing of this question [116, 143].
DC editing, activation and polarization by NK cells
In addition to NK cell activation by mature DCs, which
might preferentially take place in secondary lymphoid
tissues, activated NK cells might also influence DC mat-
uration at sites of inflammation. This signaling from NK
cells to DCs has been termed DC editing [144], and con-
sists of killing of immature or allogeneic DCs, induction of
DC maturation and modification of DC maturation for
enhanced induction of Th1-polarized adaptive immune
responses (Fig. 3). NK cells, as cytotoxic innate
lymphocytes, can directly attack susceptible target cells.
Cytotoxicity of activated NK cells is triggered if a target
cell does not provide enough inhibitory signals (absence of
MHC class I molecules or ‘‘missing self’’) or too many
activating signals (‘‘altered self’’). Due to an abundance of
activating ligands, NK cells can lyse autologous myeloid
cells, like microglia cells, macrophages and DCs, despite
their MHC class I expression. Non-activated microglia
cells were found to be susceptible to NK cell killing via
recognition by the activating NKp46 and NKG2D receptors
[145]. Furthermore, macrophages can also be targets of
editing by NK cells. In this case, TLR-activated or infected
macrophages seem to be more susceptible than non-acti-
vated macrophages and upregulate NKG2D ligands [146–
148]. Moreover, the first report documenting killing of DCs
by NK cells appeared in 1985 by Shah and colleagues
[149]. Today, it is appreciated that immature DCs can be
targets for NK cell cytotoxicity, and are more susceptible
than mature DCs [150–152]. However, the ratio between
DCs and NK cells seem to play an important role in
Fig. 3 Dendritic cell editing: killing, maturation, and Th1 polariza-
tion by natural killer cells. Sites of inflammation allow activated
natural killer (NK) cells to encounter immature dendritic cells (DCs).
1 At high NK cell/DC ratios, NK cells can kill immature DCs, due to
the engagement of the natural cytotoxicity receptors p30 and p46 and
DNAX accessory molecule 1 (NKp30, NKp46 and DNAM-1). The
low levels of HLA-E expression on immature DCs are unable to
inhibit this NK cell activation. It is thought that cytotoxic editing of
DCs by NK cell is mediated by TRAIL/DR4/5-induced apoptosis. 2
At low NK/DC ratios, NK cells can promote maturation of DCs, via
type II interferon, tumor necrosis factor and granulocyte macrophage
colony-stimulating factor (IFN-c, TNF and GM-CSF, respectively).
These cytokines induce phenotypic maturation of DCs, which
includes up-regulation of co-stimulatory and MHC molecules
(CD83, CD86, MHC class I and MHC class II). Furthermore, in
some cases, cytokine production by DCs is also induced (like IL-12
secretion). Maturation of DCs enables then to migrate into secondary
lymphoid organs (SLOs), due to the upregulation of chemokine
receptors, like C–C chemokine receptor 7 (CCR7). 3 Inside SLOs,
DCs previously activated by NK cells were found to efficiently prime
protective adaptive responses, including Th1 polarization of naı¨ve
CD4? T cells and cytotoxic responses by CD8? T cells
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whether immature DCs are targeted by NK cells. Large
numbers of activated NK cells competently kill immature
DCs [86, 153]. Furthermore, killing of immature DCs by
NK cells is mediated by NKp30, NKp46 and the activating
co-receptor DNAM-1 [87, 154, 155] in the context of
insufficient inhibitory signaling due to low HLA-E
expression by these APCs [156]. In contrast, upregulation
of MHC class I, including non-classical HLA-E molecules,
during DC maturation protects DCs against NK cell lysis
[87]. After activating NK cell receptors are engaged,
immature DCs are killed by NK cells through apoptosis
induction, via the TNF-related apoptosis-inducing ligand
(TRAIL)-death receptor 4 (DR4) pathway [153, 157]. In
addition, after homing to lymph nodes, NK cells can also
kill DCs by perforin-dependent mechanisms [158]. The
advantages of eliminating immature DCs through NK cell-
mediated cytotoxicity might be that such tolerogenic APCs
can be selectively eliminated to allow only mature DCs to
emigrate from sites of inflammation for efficient induction
of immune responses. Moreover, DC killing by NK cells
can also be harnessed clinically to remove allogeneic DCs
that could elicit graft-versus-host disease during bone
marrow transplantation, or allograft rejection [159, 160].
Contrary to DC killing by NK cells at high NK cell to
immature DC ratios, low ratios seem to promote DC
maturation and survival [86, 153]. Activated NK cells
upregulate the surface expression of co-stimulatory mole-
cules and cytokines by DCs. Both, contact-dependent
mechanisms and soluble factors promote maturation of
DCs by NK cells. After activation, NK cells can secrete
IFN-c and TNF and these cytokines induce differentiation
of monocytes into inflammatory DCs and upregulation of
co-stimulatory molecules on immature DCs [85, 86, 161,
162]. Among these, NK cells induce upregulation of CD86,
CD83 and HLA-DR expression of DCs, while DC-SIGN
expression was found to be downregulated [153]. More-
over, NK cells also boost plasmacytoid DC functions, like
their capacity to sense virus products at suboptimal con-
centrations [90]. Furthermore, DC maturation by NK cells
allows also for the upregulation of chemokine receptors for
the migration to SLOs, the site of T cell priming. Thus,
activated NK cells can mature DCs for the initiation of
adaptive immune responses. However, physiologic condi-
tions under which NK cell activation precedes DC
maturation have so far been rarely reported. The notable
exception being NK cell activation by tumors cells, which
was found to mature DCs for the priming of protective
CD8? T cell responses [163].
In addition to DC maturation, NK cells can also assist in
the polarization of Th1 responses. Especially, the
CD56bright NK cell subset in SLOs is superior in IFN-c
secretion and can thereby assist Th1 priming by DCs [58,
61, 164]. The NK cell-supported initiation of Th1 immune
responses allows the efficient elimination of tumor cells
and several intracellular pathogens [165–167]. Indeed, Ing
and Stevenson [166] showed very elegantly that Plasmo-
dium falciparum induces activation of NK cells via mature
DCs, and activated NK cells in turn augment IL-12 pro-
duction by DCs to induce Th1 polarized CD4? T cell
responses. Thus, NK cells edit DC-mediated responses by
killing tolerogenic immature DCs, by maturing DCs pri-
marily via TNF, and by assisting the priming of Th1-
polarized immune responses by secretion of IFN-c.
Conclusions
Dendritic cells have now been recognized as the most
efficient antigen-presenting cells for the initiation of innate
and adaptive immune responses. By delicately balancing
inhibitory and activating signaling, they stimulate human
NK cells, preferentially those that are enriched in T cell
areas of secondary lymphoid organs, and prevent them-
selves being killed by them at the same time. DCs
preferentially migrate to these sites after maturation is set in
motion through pathogen-associated molecular pattern
recognition in the periphery. Activated NK cells can then, in
turn, home to these peripheral sites to limit pathogen rep-
lication through cytokines and killing of infected cells, but
also edit DC populations so that only mature DCs deliver
signals from these sites to secondary lymphoid organs.
Tolerogenic immature DCs are either matured by NK cells
or destroyed at the site of infection. While the ability of NK
cells to kill immature DCs is already used clinically to
prevent graft-versus-host disease after HLA-mismatched
bone marrow transplantation, NK cell activity is not yet
consciously harnessed during vaccination by suitable
adjuvant choice, which would mature DCs optimally to
recruit these innate effector cells during immunization.
Especially, tumor immunotherapy could benefit signifi-
cantly from DC-mediated activation of NK cells.
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